What is the projected market valuation of RNA-Based Therapeutics by 2035?

The RNA-Based Therapeutics market is projected to reach a valuation of 28.11 USD Billion by 2035. Read More

What was the market valuation of RNA-Based Therapeutics in 2024?

In 2024, the RNA-Based Therapeutics market was valued at 14.65 USD Billion. Read More

What is the expected CAGR for the RNA-Based Therapeutics market from 2025 to 2035?

The expected CAGR for the RNA-Based Therapeutics market during the forecast period 2025 - 2035 is 6.1%. Read More

Which technology segment is projected to have the highest growth in the RNA-Based Therapeutics market?

The mRNA Therapeutics segment is projected to grow from 5.0 USD Billion in 2024 to 10.0 USD Billion by 2035. Read More

What are the key applications driving the RNA-Based Therapeutics market?

Key applications include Oncology, Infectious Diseases, Genetic Disorders, and Cardiovascular Diseases, with Oncology projected to grow from 5.0 USD Billion to 10.0 USD Billion. Read More

Which delivery method segment is expected to see significant growth in the RNA-Based Therapeutics market?

The Viral Vectors delivery method segment is expected to grow from 4.5 USD Billion in 2024 to 8.0 USD Billion by 2035. Read More

Who are the leading companies in the RNA-Based Therapeutics market?

Key players in the RNA-Based Therapeutics market include Moderna, BioNTech, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals. Read More

What is the projected growth for the Antisense Oligonucleotides segment in the RNA-Based Therapeutics market?

The Antisense Oligonucleotides segment is projected to grow from 2.5 USD Billion in 2024 to 4.5 USD Billion by 2035. Read More

How does the market for RNA-Based Therapeutics compare between pharmaceutical companies and research institutions?

In 2024, pharmaceutical companies accounted for 5.86 USD Billion, while research institutions accounted for 4.39 USD Billion, indicating a strong lead for pharmaceutical companies. Read More

What is the anticipated growth for the CRISPR Technology segment in the RNA-Based Therapeutics market?

The CRISPR Technology segment is anticipated to grow from 3.65 USD Billion in 2024 to 6.15 USD Billion by 2035. Read More

RNA Based Therapeutics Market

ID: MRFR/HC/17697-HCR

128 Pages

Vikita Thakur

Last Updated: April 06, 2026

RNA-Based Therapeutics Market Research Report: Size, Share, Trend Analysis By Technology (RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, CRISPR Technology), By Applications (Oncology, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases), By End Use (Pharmaceutical Companies, Research Institutions, Contract Research Organizations), By Delivery Method (Liposomes, Nanoparticles, Viral Vectors, Electroporation) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

RNA Based Therapeutics Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.1%

2024 Market Size$ 14.65 Billion

2025 Market Size$ 15.55 Billion

2035 Market Size$ 28.11 Billion

Key Players

Moderna

BioNTech

Alnylam Pharmaceuticals

Ionis Pharmaceuticals

CureVac

Arcturus Therapeutics

Trends

Technological Advancements
Regulatory Evolution
Increased Investment

Opportunities

Increased Funding for RNA Research
Growing Focus on Personalized Medicine
Rising Prevalence of Genetic Disorders

Summary Table of Contents Segmentation Methodology Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Technology (USD Billion) | |
  1. 4.1.1 RNA Interference | |
  2. 4.1.2 Antisense Oligonucleotides | |
  3. 4.1.3 mRNA Therapeutics | |
  4. 4.1.4 CRISPR Technology |
2. 4.2 Healthcare, BY Application (USD Billion) | |
  1. 4.2.1 Oncology | |
  2. 4.2.2 Infectious Diseases | |
  3. 4.2.3 Genetic Disorders | |
  4. 4.2.4 Cardiovascular Diseases |
3. 4.3 Healthcare, BY End Use (USD Billion) | |
  1. 4.3.1 Pharmaceutical Companies | |
  2. 4.3.2 Research Institutions | |
  3. 4.3.3 Contract Research Organizations |
4. 4.4 Healthcare, BY Delivery Method (USD Billion) | |
  1. 4.4.1 Liposomes | |
  2. 4.4.2 Nanoparticles | |
  3. 4.4.3 Viral Vectors | |
  4. 4.4.4 Electroporation |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Moderna (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 BioNTech (DE) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Alnylam Pharmaceuticals (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Ionis Pharmaceuticals (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 CureVac (DE) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Arcturus Therapeutics (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Translate Bio (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Sarepta Therapeutics (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Dicerna Pharmaceuticals (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TECHNOLOGY |
7. 6.4 US MARKET ANALYSIS BY APPLICATION |
8. 6.5 US MARKET ANALYSIS BY END USE |
9. 6.6 US MARKET ANALYSIS BY DELIVERY METHOD |
10. 6.7 CANADA MARKET ANALYSIS BY TECHNOLOGY |
11. 6.8 CANADA MARKET ANALYSIS BY APPLICATION |
12. 6.9 CANADA MARKET ANALYSIS BY END USE |
13. 6.10 CANADA MARKET ANALYSIS BY DELIVERY METHOD |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TECHNOLOGY |
16. 6.13 GERMANY MARKET ANALYSIS BY APPLICATION |
17. 6.14 GERMANY MARKET ANALYSIS BY END USE |
18. 6.15 GERMANY MARKET ANALYSIS BY DELIVERY METHOD |
19. 6.16 UK MARKET ANALYSIS BY TECHNOLOGY |
20. 6.17 UK MARKET ANALYSIS BY APPLICATION |
21. 6.18 UK MARKET ANALYSIS BY END USE |
22. 6.19 UK MARKET ANALYSIS BY DELIVERY METHOD |
23. 6.20 FRANCE MARKET ANALYSIS BY TECHNOLOGY |
24. 6.21 FRANCE MARKET ANALYSIS BY APPLICATION |
25. 6.22 FRANCE MARKET ANALYSIS BY END USE |
26. 6.23 FRANCE MARKET ANALYSIS BY DELIVERY METHOD |
27. 6.24 RUSSIA MARKET ANALYSIS BY TECHNOLOGY |
28. 6.25 RUSSIA MARKET ANALYSIS BY APPLICATION |
29. 6.26 RUSSIA MARKET ANALYSIS BY END USE |
30. 6.27 RUSSIA MARKET ANALYSIS BY DELIVERY METHOD |
31. 6.28 ITALY MARKET ANALYSIS BY TECHNOLOGY |
32. 6.29 ITALY MARKET ANALYSIS BY APPLICATION |
33. 6.30 ITALY MARKET ANALYSIS BY END USE |
34. 6.31 ITALY MARKET ANALYSIS BY DELIVERY METHOD |
35. 6.32 SPAIN MARKET ANALYSIS BY TECHNOLOGY |
36. 6.33 SPAIN MARKET ANALYSIS BY APPLICATION |
37. 6.34 SPAIN MARKET ANALYSIS BY END USE |
38. 6.35 SPAIN MARKET ANALYSIS BY DELIVERY METHOD |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USE |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY DELIVERY METHOD |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TECHNOLOGY |
45. 6.42 CHINA MARKET ANALYSIS BY APPLICATION |
46. 6.43 CHINA MARKET ANALYSIS BY END USE |
47. 6.44 CHINA MARKET ANALYSIS BY DELIVERY METHOD |
48. 6.45 INDIA MARKET ANALYSIS BY TECHNOLOGY |
49. 6.46 INDIA MARKET ANALYSIS BY APPLICATION |
50. 6.47 INDIA MARKET ANALYSIS BY END USE |
51. 6.48 INDIA MARKET ANALYSIS BY DELIVERY METHOD |
52. 6.49 JAPAN MARKET ANALYSIS BY TECHNOLOGY |
53. 6.50 JAPAN MARKET ANALYSIS BY APPLICATION |
54. 6.51 JAPAN MARKET ANALYSIS BY END USE |
55. 6.52 JAPAN MARKET ANALYSIS BY DELIVERY METHOD |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USE |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY DELIVERY METHOD |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY |
61. 6.58 MALAYSIA MARKET ANALYSIS BY APPLICATION |
62. 6.59 MALAYSIA MARKET ANALYSIS BY END USE |
63. 6.60 MALAYSIA MARKET ANALYSIS BY DELIVERY METHOD |
64. 6.61 THAILAND MARKET ANALYSIS BY TECHNOLOGY |
65. 6.62 THAILAND MARKET ANALYSIS BY APPLICATION |
66. 6.63 THAILAND MARKET ANALYSIS BY END USE |
67. 6.64 THAILAND MARKET ANALYSIS BY DELIVERY METHOD |
68. 6.65 INDONESIA MARKET ANALYSIS BY TECHNOLOGY |
69. 6.66 INDONESIA MARKET ANALYSIS BY APPLICATION |
70. 6.67 INDONESIA MARKET ANALYSIS BY END USE |
71. 6.68 INDONESIA MARKET ANALYSIS BY DELIVERY METHOD |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY |
73. 6.70 REST OF APAC MARKET ANALYSIS BY APPLICATION |
74. 6.71 REST OF APAC MARKET ANALYSIS BY END USE |
75. 6.72 REST OF APAC MARKET ANALYSIS BY DELIVERY METHOD |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TECHNOLOGY |
78. 6.75 BRAZIL MARKET ANALYSIS BY APPLICATION |
79. 6.76 BRAZIL MARKET ANALYSIS BY END USE |
80. 6.77 BRAZIL MARKET ANALYSIS BY DELIVERY METHOD |
81. 6.78 MEXICO MARKET ANALYSIS BY TECHNOLOGY |
82. 6.79 MEXICO MARKET ANALYSIS BY APPLICATION |
83. 6.80 MEXICO MARKET ANALYSIS BY END USE |
84. 6.81 MEXICO MARKET ANALYSIS BY DELIVERY METHOD |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY |
86. 6.83 ARGENTINA MARKET ANALYSIS BY APPLICATION |
87. 6.84 ARGENTINA MARKET ANALYSIS BY END USE |
88. 6.85 ARGENTINA MARKET ANALYSIS BY DELIVERY METHOD |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DELIVERY METHOD |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USE |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DELIVERY METHOD |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USE |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DELIVERY METHOD |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY |
103. 6.100 REST OF MEA MARKET ANALYSIS BY APPLICATION |
104. 6.101 REST OF MEA MARKET ANALYSIS BY END USE |
105. 6.102 REST OF MEA MARKET ANALYSIS BY DELIVERY METHOD |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY END USE, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY DELIVERY METHOD, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY DELIVERY METHOD, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY DELIVERY METHOD, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

RNA Based Therapeutics Market Segmentation

RNA Based Therapeutics Market By Technology (USD Billion, 2025-2035)

RNA Interference
Antisense Oligonucleotides
mRNA Therapeutics
CRISPR Technology

RNA Based Therapeutics Market By Application (USD Billion, 2025-2035)

Oncology
Infectious Diseases
Genetic Disorders
Cardiovascular Diseases

RNA Based Therapeutics Market By End Use (USD Billion, 2025-2035)

RNA Based Therapeutics Market Companies
Research Institutions
Contract Research Organizations

RNA Based Therapeutics Market By Delivery Method (USD Billion, 2025-2035)

Liposomes
Nanoparticles
Viral Vectors
Electroporation

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”